Dose Optimization of Moxifloxacin and Linezolid Against Tuberculosis Using Mathematical Modeling and Simulation

Tuberculosis (TB) is the leading infectious disease killer globally, resulting in 1.8 million deaths a year [1]. A third of the world population is infected with TB today [2]. Global emergence of multidrug-resistant (MDR) TB (resistant to at least isoniazid and rifampicin) makes the TB epidemic an even greater problem as treatment outcomes among such patients are substantially worse than those for drug susceptible TB [1,2]. The World Health Organization (WHO) reports approximately half a million new cases of MDR TB per year [2].

Source: International Journal of Antimicrobial Agents - October 29, 2018 Category: Drugs & Pharmacology Authors: M. Tobias Heinrichs, George L. Drusano, David L. Brown, Michael S. Maynard, Sherwin K.B. Sy, Kenneth H. Rand, Charles A. Peloquin, Arnold Louie, Hartmut Derendorf Source Type: research